Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.

As of March 31, 2009, Optimer held cash, cash equivalents and short-term investments of $62.6 million.

"We are off to a strong start in 2009," said Michael N. Chang, Ph.D., Optimer's President and CEO. "We announced plans to prepare a marketing application in Europe based on the results of the first fidaxomicin Phase 3 trial for Clostridium difficile infection. We also reported positive top-line results from the second prulifloxacin Phase 3 trial for the treatment of infectious diarrhea."

Recent Corporate Highlights

  • Announced plans to prepare a Marketing Authorization Application (MAA) for submission with the European Medicines Agency (EMEA) for approval of fidaxomicin as an oral treatment for Clostridium difficile infection (CDI) based on the results from the Company's first Phase 3 fidaxomicin trial.
  • Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
  • Announced positive results from the second pivotal Phase 3 trial of prulifloxacin for the treatment of infectious diarrhea. The tri
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE MKT: ... diseases, with a focus on protecting the microbiome, announced today ... to present at the 27th Annual ROTH Conference being held ... Niguel in Dana Point, CA. ... 10, 2015 at 1:00 p.m. (Pacific Time). A ...
(Date:3/3/2015)... INCLINE VILLAGE, Nev. , March 3, 2015 /PRNewswire/ ... PDLI ) today announced that the third of ... was voluntarily dismissed without prejudice. On February ... the Company last September on behalf of a putative ... PDL Biopharma, Inc., et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), ...
(Date:3/3/2015)... , March 2, 2015  Phillip Sharp, Institute Professor at ... of the Department of Biology and the Koch Institute for Integrative ... at Heritage Day , May 14, at the ... the Othmer Gold Medal since it was first awarded ... "In 1977 Phil Sharp gave the scientific world ...
(Date:3/2/2015)... 2015 Shimadzu Scientific Instruments will showcase ... LCMS and marijuana analysis at the Pittcon 2015 conference ... 12 at the Ernest N. Morial Convention Center in ... booth 3121 to discuss laboratory challenges with Shimadzu’s technical ... products help save time, money and effort in the ...
Breaking Biology Technology:Synthetic Biologics to Present at the 27th Annual ROTH Conference 2PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3
... RICHMOND, Virginia, ROSH HA,AYIN, Israel, June 16 ,EnzySurge ... advanced,chronic wound management, recently announced the formation of ... and practitioners with diversified expertise in chronic wounds.,The ... MD, PhD, Diane L.,Krasner, PhD RN, FAAN, Joseph ...
... June 16 Alexandria Real Estate,Equities, Inc. (NYSE: ... 100 life science,executives from around the world on ... environmentally sustainable operations in the San Diego life,science ... being held in,conjunction with the Biotechnology Industry Organization,s ...
... data management product for the, hospital ... connection, BOTHELL, Wash., June 16 Cardiac ... flagship HeartCentrix(R) data,management product for the hospital market. ... across all facilities within a,hospital network. Cardiac Science ...
Cached Biology Technology:EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 2Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 3Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 4Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 2Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 3Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 4
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Washington, D.C. (July 13, 2010) -- The 52nd ... Medicine (AAPM) convenes from July18 - 22, 2010 ... organization in medical physics, a broadly-based scientific and ... medicine and biology. Its membership includes medical physicists ...
... An estimated 5 percent of the Key West, Fla., population ... to dengue virus in 2009, according to a report from ... Florida Department of Health. After three initial locally acquired ... CDC and the Florida Department of Health conducted a study ...
... mineral processing technology company and licensee of NJIT, has ... cement, fly ash, and other cementitious materials to a ... range from $30-75 per ton, depending on feedstock, ... production using proven equipment. Flyanic, along with ...
Cached Biology News:Nanotech medicine, tumor tracking, new technologies and more 2Nanotech medicine, tumor tracking, new technologies and more 3Nanotech medicine, tumor tracking, new technologies and more 4Nanotech medicine, tumor tracking, new technologies and more 5Nanotech medicine, tumor tracking, new technologies and more 6Nanotech medicine, tumor tracking, new technologies and more 7Nanotech medicine, tumor tracking, new technologies and more 8Nanotech medicine, tumor tracking, new technologies and more 9Nanotech medicine, tumor tracking, new technologies and more 10Nanotech medicine, tumor tracking, new technologies and more 11Nanotech medicine, tumor tracking, new technologies and more 12Nanotech medicine, tumor tracking, new technologies and more 13Nanotech medicine, tumor tracking, new technologies and more 14Nanotech medicine, tumor tracking, new technologies and more 15Nanotech medicine, tumor tracking, new technologies and more 16Nanotech medicine, tumor tracking, new technologies and more 17Report suggests nearly 5 percent exposed to dengue virus in Key West 2
... Gel extraction kit, 100 preps Storage: The ... temperature. For longer storage, keep all contents of ... spin column purification kit utilizes a silica-gel based ... DNA fragments in the presence of specialized binding ...
The Sony UPD895 printer is used to print data captured with the Gel Doc XR and ChemiDoc XRS gel documentation systems as well as the VersaDoc imaging systems....
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
... with 384-well reaction module is used for ... equipped with an interchangeable, 384-well reaction module ... monitoring and control and ramp rates that ... includes the iCycler base with 384-well reaction ...
Biology Products: